• Mythic Therapeutics

  Participated · Series B · Dec 2021

  Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit improved therapeutic index and efficacy. Its FateControl technology increases ADC internalization in targeted tissues while reducing payload release in non-target tissues, aiming to improve performance independent of linker and payload. The company's lead program targets lung cancer and the firm plans to expand ADC use across additional indications and patient profiles. Proceeds from the announced financing will finance the lead program through first-in-human clinical studies and support pipeline development. Mythic positions its approach as a new dimension of ADC technology focused on manipulating ADC fate within the cell. Leadership includes co-founders Alex Nichols (President and CEO) and Brian Fiske (Chief Scientific Officer); the company is based in Waltham, Massachusetts.

• InterVenn

  Led · Series C · Aug 2021

  InterVenn Biosciences operates a proprietary glycoproteomics biomarker interrogation platform that combines mass spectrometry with AI to enable next-generation precision medicine. The platform has been used to develop 16 clinical use cases across oncology and other indications. The company is developing Dawn™, a liquid-biopsy assay for predicting response to immune checkpoint inhibitors, which it planned to commercialize in 2022. With new funding, InterVenn intends to accelerate development and commercialization of Dawn and to expand investment in glycoproteomics-based liquid biopsy solutions across the oncology spectrum (screening through therapy response monitoring) and into non-oncology applications. The financing will also enable the company to expand its partnership ecosystem to accelerate development and commercialization of new clinical solutions and broaden insights into new biomarkers and therapies. InterVenn is based in South San Francisco, California. InterVenn develops a proprietary glycoproteomic biomarker‑interrogation platform that combines mass spectrometry with an AI neural network (PiP™) and powers the Vista™ research product. Vista™ provides application‑specific disease classifier panels across more than a dozen oncology indications and has been used to predict response to checkpoint‑inhibitor treatment. The company is commercializing a High‑Throughput‑Glycoproteomic LDT for ovarian cancer and is enrolling patients in V.O.C.A.L.™, a multicenter international trial whose interim results show the InterVenn test outperforming CA 125 in specificity and sensitivity. InterVenn plans to use new funds to scale commercialization of the ovarian diagnostic, service increasing partnership platform demand, and accelerate development of immuno‑oncology treatment‑response and colorectal cancer indications. The company is headquartered in South San Francisco and is commissioning new office and laboratory space there. Leadership additions include John Leite, Ph.D., as Chief Business Officer and David Michael of Anzu Partners joining the board. InterVenn BioSciences develops an AI-driven mass spectrometry glycoproteomics platform to rapidly characterize post-translational modifications and identify clinically relevant biomarkers. The company leverages mass spectrometry, high-resolution PTM characterization, and artificial intelligence to streamline glycoproteomics workflows and improve reproducibility across sample collection, processing, and instrument ingestion. Its first product is a blood-based ovarian cancer diagnostic that is undergoing analytical and clinical validation. Once validation and regulatory processes are completed, InterVenn plans to offer the test as a laboratory diagnostic. The platform is positioned for additional applications across cancers, autoimmunity, fibrosis, and neurodegeneration. The company is headquartered in Redwood City, California.

• Strata Oncology

  Participated · Series C · Jul 2021

  Strata Oncology is a precision oncology company based in Ann Arbor, Mich., focused on expanding a comprehensive genomic and transcriptomic profiling platform. The platform integrates comprehensive genomic profiling with highly quantitative RNA expression profiling to deliver molecular insights from a single, minute tumor tissue specimen. Strata offers a portfolio of treatment selection tests for solid tumors and is developing a personalized minimal residual disease (MRD) assay for early-stage cancers. The company is also advancing a pipeline of novel RNA-based treatment selection tests for solid tumors. Financially, Strata closed a $90M Series C and has raised over $130M in total since inception. The company is led by co-founder and CEO Dan Rhodes, Ph.D. Strata Oncology is an Ann Arbor, Mich.-based precision oncology platform that systematizes tumor molecular profiling and precision therapy trials across a network of health systems and pharma partners. The company integrates molecular profiling and precision therapy trials with routine care to enable system-wide precision oncology programs and provide a mechanism for rapid, predictable enrollment in precision therapy trials. Strata offers a tumor molecular profiling assay, StrataNGS, and develops clinical-genomic data and software solutions to streamline health system workflows. The company plans to expand its Strata Precision Oncology Network of adopting health systems, further develop its clinical-genomic data and software, and submit StrataNGS for FDA approval. It also intends to launch the PATH master therapeutic protocol to support rapid and cost-effective indication expansion studies for on-market drugs. Strata is led by CEO Dan Rhodes, PhD, and recently completed a significant Series B financing. Strata Oncology provides tumor sequencing to advanced cancer patients and maintains a portfolio of matching clinical trials. The company completed a $12M Series A financing to accelerate development of its tumor sequencing operation and to implement the Strata Trial, a nationwide effort to substantially increase enrollments in precision medicine clinical trials. It is based in Ann Arbor, Mich. Strata's core offering pairs next-generation sequencing-based tumor profiling with trial matching to connect patients to precision medicine studies. The company has a strategic partnership with Thermo Fisher Scientific, which will serve as technology provider and supply Ion S5 XL systems, AmpliSeq technology, and Oncomine assays. Strata was co-founded by Dan Rhodes (CEO), oncologist Keith Flaherty, M.D., and pathologist Scott Tomlins, M.D., Ph.D.

• Athira Pharma

  Participated · Series B · Jun 2020

  Athira Pharma is a Seattle, WA-based clinical-stage drug development company advancing first-in-class regenerative therapies aimed at restoring brain function. Led by Dr. Leen Kawas, the company is advancing its lead therapeutic candidate, NDX-1017, a novel small molecule in later-stage clinical trials for Alzheimer’s. Athira describes its approach as bold and innovative therapies to improve human health for people impacted by brain disorders. The company intends to use newly raised funds to support a Phase 2/3 Alzheimer’s clinical trial of NDX-1017. The article does not provide operating metrics such as revenue or user numbers. M3 Biotechnology is a Seattle-based therapeutics company developing small-molecule treatments for Alzheimer’s disease. The company focuses on re-establishing lost connections between brain cells to improve cognitive function. Led by CEO Leen Kawas, M3’s lead candidate is NDX-1017. The company is planning a first-in-humans Phase 1a clinical trial to evaluate NDX-1017’s safety and dosing. M3 raised $1.4M in a second funding round and has secured $14M in total financing to date. Proceeds from the latest round will support the launch of human trials, with backers including Dolby Family Ventures and the Alzheimer’s Drug Discovery Foundation.

No current team members are available.